Delivery Order SPE2DR25D1041-SPE2DR26FHP7V
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,948.80 to AmerisourceBergen Drug Corp for AMLOD-VALSA-HCTZ 10-320-25 MG 30S pharmaceutical products, with an ultimate completion date of September 23, 2025. This firm fixed-price, non-set-aside contract was awarded on September 22, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,054.44 to AmerisourceBergen Drug Corp for AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a pharmaceutical product, on March 12, 2025, with completion expected by March 13, 2025. This competitively awarded, firm fixed-price contract was issued without set-aside status and will be performed at the vendor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $3,401.50 to AmerisourceBergen Drug Corp for pharmaceutical supplies, specifically AMLOD-VALSA-HCTZ 10-320-25 MG in a 30-count supply. This firm fixed-price delivery order, issued on August 21, 2025, with an ultimate completion date of August 22, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no...
- The Defense Logistics Agency awarded a $2,069.16 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of AMLOD-VALSA-HCTZ 5-160-25 MG in 30-count packaging. The contract, which is non-set-aside and competitively awarded on a firm fixed price basis, is scheduled for completion by August 5, 2025, with performance to occur at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement...
- This is a $3,745.42 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order was placed against the company's $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order is for AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a...
- The Defense Logistics Agency awarded a $1,275.81 delivery order to Amerisourcebergen Drug Corporation for 4561609445 AMLOD-VALSA-HCTZ 5-160-25 MG 30S. The firm fixed price order is being fulfilled by Amerisourcebergen's Conshohocken, Pennsylvania facility on behalf of its parent company, Amerisourcebergen Corporation. As a major provider of pharmaceuticals and medical supplies to the Department of Defense, this order for hypertension medication supports the Defense Logistics Agency's mission...
- This $4,759.35 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The contract provides for the supply of AMLOD-VALSA-HCTZ 10-320-25 MG 30S, a pharmaceutical product, with a completion date of August 12, 2024. Amerisourcebergen is a major supplier of pharmaceutical and medical products to the U.S. federal government, including military treatment facilities and veterans' healthcare...
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp, valued at $1,812.56, for the supply of Amlodipine-Valsartan 10-160 mg tablets (30-count supply) with an ultimate completion date of August 27, 2025. This non-set-aside contract represents a routine pharmaceutical procurement executed through the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $11,424.98 to AmerisourceBergen Drug Corp for the supply of AMLODIPINE-VALSARTAN-HYDROCHLOROTHIAZIDE 5-160-12.5 mg tablets in a 30-count quantity. This competitive, non-set-aside award was executed on August 7, 2025, with an ultimate completion date of August 8, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The firm fixed price delivery order structure reflects the...
- The Defense Logistics Agency awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply AMLOD-VALSA-HCTZ 5-160-25 MG 30S pharmaceuticals. The $1,315.90 order has a completion date of January 12, 2024 and was issued on January 11, 2024. Amerisourcebergen Drug Corp, as a prime contractor, has provided a range of pharmaceutical and medical supply products to the Defense Logistics Agency, including specialty, brand name,...
- SPE2DR25D1041Indefinite Delivery Contract
- SPE2DR25D1041-SPE2DR26FHP7VDelivery Order
The Defense Logistics Agency awarded a $1,715.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp for AMLOD-VALSA-HCTZ 10-160-12.5MG 30S pharmaceutical products, with an ultimate completion date of October 24, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a critical pharmaceutical distributor for federal medical procurement needs. AmerisourceBergen Drug Corp, a major for-profit pharmaceutical distributor headquartered in Pennsylvania, maintains an extensive federal contract portfolio with the Defense Logistics Agency supporting military and veteran healthcare systems. The company's SPE2DX prime contract functions as a comprehensive global pharmaceutical support vehicle enabling supply of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for the specified medication quantity exemplifies the company's ongoing role in fulfilling federal medical supply requirements through the DLA's Medical Supply Chain, with the agency planning future Pharmaceutical Prime Vendor Global Program Generation V contracts to expand regional coverage among multiple contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 10/23/25 |